Ablynx (ABLYF) Stock Price, News & Analysis

Company Overview

Ablynx plc is a biopharmaceutical company specializing in the discovery and development of nanobody-based therapeutics. Nanobodies are single-domain antibody fragments derived from camelid heavy-chain antibodies that combine high target specificity with favorable stability and tissue penetration. Ablynx applies proprietary platforms to engineer these molecules against a range of disease targets, with a particular focus on rare hematological disorders, immunology, and oncology.

The company’s pipeline has historically included caplacizumab (Cablivi®), which received approval in the United States and Europe for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In addition to advancing its own therapeutic candidates, Ablynx has entered partnerships and licensing agreements with major pharmaceutical companies to leverage its nanobody platform for oncology and inflammatory disease programs. Research and development activities are supported by integrated discovery, preclinical and clinical capabilities in Europe and North America.

Founded in 2001 as a spin-out from the Flanders Institute for Biotechnology and Ghent University, Ablynx is headquartered in Ghent, Belgium, with additional research operations in Cambridge, Massachusetts. In January 2018, the company was acquired by Sanofi, becoming part of its global R&D network. Ablynx operates under the guidance of an experienced management team with deep expertise in antibody engineering, drug development and regulatory affairs, serving patient populations across Europe, North America and emerging markets.

Key Stats

• Today's Range: $50.63 to $50.63
• 50-Day Range: $50.63 to $50.63
• 52-Week Range: $12.50 to $55.04
• Volume: N/A
• Average Volume: 5,063 shs
• Market Capitalization: $3.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ABLYF
• Previous Symbol: NASDAQ:ABLYF
• CIK: N/A
• Web: www.ablynx.com
• Phone: 329-262-0000
• Fax: N/A
• Employees: N/A
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $62.73 million
• Price / Sales: 60.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 18.68

Miscellaneous

• Outstanding Shares: 75,250,000
• Free Float: N/A
• Market Cap: $3.81 billion
• Optionable: Not Optionable
• Beta: 1.99